Orange Book product · Generic (ANDA)
GABAPENTIN
GABAPENTIN
At a glance
Mar 14, 2016
Approved
Generic (ANDA)
Application
AA
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 14, 2016
10 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
GABAPENTIN
Strength
250MG/5ML
Dosage form
SOLUTION
Route
ORAL
TE code
AA
Application
ANDA 091286
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of GABAPENTIN
- 2000NEURONTINBrand (NDA)
NDA 021129 · VIATRIS
- 1993NEURONTINBrand (NDA)
NDA 020235 · VIATRIS
- 2026GABAPENTINGeneric (ANDA)
ANDA 219814 · PRINSTON INC
- 2025GABAPENTINGeneric (ANDA)
ANDA 219319 · SENORES PHARMS
- 2024GABAPENTINGeneric (ANDA)
ANDA 203643 · ABON PHARMS LLC
- 2024GABAPENTINGeneric (ANDA)
ANDA 218075 · ANNORA PHARMA
- 2024GABAPENTINGeneric (ANDA)
ANDA 216252 · EPIC PHARMA LLC
- 2024GABAPENTINGeneric (ANDA)
ANDA 217682 · ANNORA PHARMA
- 2023GABAPENTINGeneric (ANDA)
ANDA 208928 · IPCA LABS LTD
- 2023GABAPENTINGeneric (ANDA)
ANDA 217546 · LAURUS
- 2023GABAPENTINGeneric (ANDA)
ANDA 217116 · GRANULES
- 2023GABAPENTINGeneric (ANDA)
ANDA 216492 · RUBICON RESEARCH
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
